Thrombocythemia, EssentialPolycythemia VeraThrombocytosisJanus Kinase 2Myeloproliferative DisordersPrimary MyelofibrosisReceptors, ThrombopoietinPlatelet CountThrombopoietinThrombosisCarbazilquinoneMegakaryocytesHydroxyureaPrognosisPipobromanRetrospective StudiesFollow-Up StudiesLeukocytosisMutationGranulocytesMutation, MissenseSurvival AnalysisThrombopoiesisSplenomegalyTumor Markers, BiologicalErythrocyte InclusionsAnemia, RefractoryBlood PlateletsPolycythemiaBone MarrowSurvival RateThrombophiliaCoagulantsNeoplasm StagingLeukemia, Myeloid, Chronic, Atypical, BCR-ABL NegativeTreatment OutcomeAmino Acid SubstitutionHemorrhageRisk FactorsPregnancy Complications, HematologicPlatelet Aggregation InhibitorsWorld Health OrganizationPredictive Value of TestsDisease-Free SurvivalMultivariate AnalysisGPI-Linked ProteinsKaplan-Meier EstimateThrombocytopeniaProportional Hazards ModelsCohort StudiesDisease ProgressionHemangioma, CavernousProspective StudiesQuinazolinesReceptors, CytokineDNA Mutational AnalysisImmunohistochemistryTime FactorsIsoantigensPoint Mutation